These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37989909)

  • 41. Gaps in Guideline-Based Lipid-Lowering Therapy for Secondary Prevention in the United States: A Retrospective Cohort Study of 322 153 Patients.
    Navar AM; Kolkailah AA; Gupta A; Gillard KK; Israel MK; Wang Y; Peterson ED
    Circ Cardiovasc Qual Outcomes; 2023 Aug; 16(8):533-543. PubMed ID: 37529931
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial.
    Vassy JL; Gaziano JM; Green RC; Ferguson RE; Advani S; Miller SJ; Chun S; Hage AK; Seo SJ; Majahalme N; MacMullen L; Zimolzak AJ; Brunette CA
    JAMA Netw Open; 2020 Dec; 3(12):e2027092. PubMed ID: 33270123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry.
    Lowenstern AM; Li S; Navar AM; Roger VL; Robinson JG; Goldberg AC; Virani SS; Lee LV; Wilson PWF; Louie MJ; Peterson ED; Wang TY
    J Am Heart Assoc; 2018 Sep; 7(18):e009251. PubMed ID: 30371214
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
    Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
    JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline.
    Pokharel Y; Steinberg L; Chan W; Akeroyd JM; Jones PH; Nambi V; Nasir K; Petersen L; Ballantyne CM; Virani SS
    Atherosclerosis; 2016 Mar; 246():115-20. PubMed ID: 26773472
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evolving Management of Low-Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum.
    Wilkinson MJ; Lepor NE; Michos ED
    J Am Heart Assoc; 2023 Jun; 12(11):e028892. PubMed ID: 37260036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US.
    Cannon CP; de Lemos JA; Rosenson RS; Ballantyne CM; Liu Y; Gao Q; Palagashvilli T; Alam S; Mues KE; Bhatt DL; Kosiborod MN;
    JAMA Cardiol; 2021 Jun; 6(9):1-9. PubMed ID: 34132735
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines.
    Mortensen MB; Tybjærg-Hansen A; Nordestgaard BG
    JAMA Cardiol; 2022 Aug; 7(8):836-843. PubMed ID: 35793078
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: Results From the Population-Based Rotterdam Study.
    Pavlovic J; Greenland P; Deckers JW; Brugts JJ; Kavousi M; Dhana K; Ikram MA; Hofman A; Stricker BH; Franco OH; Leening MJ
    JAMA Cardiol; 2016 Sep; 1(6):708-13. PubMed ID: 27439175
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline.
    Grundy SM; Stone NJ;
    Ann Intern Med; 2019 Jun; 170(11):779-783. PubMed ID: 31132793
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals.
    Underberg J; Toth PP; Rodriguez F
    Postgrad Med; 2022 Nov; 134(8):752-762. PubMed ID: 36004573
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases.
    Choi SY; Yang BR; Kang HJ; Park KS; Kim HS
    Korean J Intern Med; 2020 May; 35(3):593-604. PubMed ID: 31752475
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
    Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
    BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Clinical Guide to Combination Lipid-Lowering Therapy.
    Russell C; Sheth S; Jacoby D
    Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Trends in low-density lipoprotein cholesterol goal achievement and changes in lipid-lowering therapy after incident atherosclerotic cardiovascular disease: Danish cohort study.
    Ersbøll AK; Kristensen MS; Nybo M; Hede SM; Mikkelsen KH; Gislason G; Lytken Larsen M; Green A
    PLoS One; 2023; 18(5):e0286376. PubMed ID: 37256879
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the European and US guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease.
    Delabays B; de La Harpe R; Vollenweider P; Fournier S; Müller O; Strambo D; Graham I; Visseren FLJ; Nanchen D; Marques-Vidal P; Vaucher J
    Eur J Prev Cardiol; 2023 Nov; 30(17):1856-1864. PubMed ID: 37290056
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
    Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
    Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
    Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC
    J Am Coll Cardiol; 2017 Oct; 70(14):1785-1822. PubMed ID: 28886926
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat.
    Mortensen MB; Nordestgaard BG
    JAMA Cardiol; 2019 Nov; 4(11):1131-1138. PubMed ID: 31577339
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Atherosclerotic Cardiovascular Disease in Women: Providing Protection With Lipid-altering Agents.
    Hiles M; Simmons A; Hilleman D; Gibson CA; Backes JM
    Clin Ther; 2023 Nov; 45(11):1127-1136. PubMed ID: 37770308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.